For IDH-mutant gliomas, the absent ADC-MGMT correlation may reflect metabolic homogeneity rather than biomarker failure, consistent with 2-hydroxyglutarate-driven epigenetic modulation. Here, IDH2 is linked to central nervous system cancer.